Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Systemic mastocytosis

Study of BLU-263 in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Expanded Access Program (EAP) for Avapritinib in Patients With AdvSM Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE™) for High Risk Heme Malignancies Adaptation of the Questionnaire “Regarding Patient’s Quality of Life With Mastocytosis” in the French Language A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent and Smoldering Systemic Mastocytosis Treatment of Indolent Systemic Mastocytosis With PA101 (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Evaluation of Response of Dasatinib to Treat Mastocytosis A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 Midostaurin in Indolent Systemic Mastocytosis Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Use of Tamoxifen in Systemic Mastocytosis Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis Imatinib in KIT-negative Systemic Mastocytosis Obatoclax for Systemic Mastocytosis